1028 related articles for article (PubMed ID: 32066536)
41. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial.
Gibson PG; Yang IA; Upham JW; Reynolds PN; Hodge S; James AL; Jenkins C; Peters MJ; Marks GB; Baraket M; Powell H; Taylor SL; Leong LEX; Rogers GB; Simpson JL
Lancet; 2017 Aug; 390(10095):659-668. PubMed ID: 28687413
[TBL] [Abstract][Full Text] [Related]
42. The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study.
McDowell PJ; Diver S; Yang F; Borg C; Busby J; Brown V; Shrimanker R; Cox C; Brightling CE; Chaudhuri R; Pavord ID; Heaney LG;
Lancet Respir Med; 2021 Oct; 9(10):1174-1184. PubMed ID: 33971168
[TBL] [Abstract][Full Text] [Related]
43. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.
Pavord ID; Korn S; Howarth P; Bleecker ER; Buhl R; Keene ON; Ortega H; Chanez P
Lancet; 2012 Aug; 380(9842):651-9. PubMed ID: 22901886
[TBL] [Abstract][Full Text] [Related]
44. Prospective Open-Label Study of 48-Week Subcutaneous Administration of Mepolizumab in Japanese Patients With Severe Eosinophilic Asthma.
Kurosawa M; Sutoh E
J Investig Allergol Clin Immunol; 2019; 29(1):40-45. PubMed ID: 29957591
[TBL] [Abstract][Full Text] [Related]
45. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma.
Rabe KF; Nair P; Brusselle G; Maspero JF; Castro M; Sher L; Zhu H; Hamilton JD; Swanson BN; Khan A; Chao J; Staudinger H; Pirozzi G; Antoni C; Amin N; Ruddy M; Akinlade B; Graham NMH; Stahl N; Yancopoulos GD; Teper A
N Engl J Med; 2018 Jun; 378(26):2475-2485. PubMed ID: 29782224
[TBL] [Abstract][Full Text] [Related]
46. Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study.
Khurana S; Brusselle GG; Bel EH; FitzGerald JM; Masoli M; Korn S; Kato M; Albers FC; Bradford ES; Gilson MJ; Price RG; Humbert M
Clin Ther; 2019 Oct; 41(10):2041-2056.e5. PubMed ID: 31447130
[TBL] [Abstract][Full Text] [Related]
47. Tezepelumab in Adults with Uncontrolled Asthma.
Corren J; Parnes JR; Wang L; Mo M; Roseti SL; Griffiths JM; van der Merwe R
N Engl J Med; 2017 Sep; 377(10):936-946. PubMed ID: 28877011
[TBL] [Abstract][Full Text] [Related]
48. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial.
Martinez FD; Chinchilli VM; Morgan WJ; Boehmer SJ; Lemanske RF; Mauger DT; Strunk RC; Szefler SJ; Zeiger RS; Bacharier LB; Bade E; Covar RA; Friedman NJ; Guilbert TW; Heidarian-Raissy H; Kelly HW; Malka-Rais J; Mellon MH; Sorkness CA; Taussig L
Lancet; 2011 Feb; 377(9766):650-7. PubMed ID: 21324520
[TBL] [Abstract][Full Text] [Related]
49. Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial.
Papi A; Corradi M; Pigeon-Francisco C; Baronio R; Siergiejko Z; Petruzzelli S; Fabbri LM; Rabe KF
Lancet Respir Med; 2013 Mar; 1(1):23-31. PubMed ID: 24321801
[TBL] [Abstract][Full Text] [Related]
50. Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study.
Menzies-Gow A; Wechsler ME; Brightling CE; Korn S; Corren J; Israel E; Chupp G; Bednarczyk A; Ponnarambil S; Caveney S; Almqvist G; Gołąbek M; Simonsson L; Lawson K; Bowen K; Colice G;
Lancet Respir Med; 2023 May; 11(5):425-438. PubMed ID: 36702146
[TBL] [Abstract][Full Text] [Related]
51. Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
Russell RJ; Chachi L; FitzGerald JM; Backer V; Olivenstein R; Titlestad IL; Ulrik CS; Harrison T; Singh D; Chaudhuri R; Leaker B; McGarvey L; Siddiqui S; Wang M; Braddock M; Nordenmark LH; Cohen D; Parikh H; Colice G; Brightling CE;
Lancet Respir Med; 2018 Jul; 6(7):499-510. PubMed ID: 29793857
[TBL] [Abstract][Full Text] [Related]
52. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial.
Diver S; Khalfaoui L; Emson C; Wenzel SE; Menzies-Gow A; Wechsler ME; Johnston J; Molfino N; Parnes JR; Megally A; Colice G; Brightling CE;
Lancet Respir Med; 2021 Nov; 9(11):1299-1312. PubMed ID: 34256031
[TBL] [Abstract][Full Text] [Related]
53. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis.
Busse WW; Wenzel SE; Casale TB; FitzGerald JM; Rice MS; Daizadeh N; Deniz Y; Patel N; Harel S; Rowe PJ; Graham NMH; O'Riordan T; Pavord ID
Lancet Respir Med; 2021 Oct; 9(10):1165-1173. PubMed ID: 34181876
[TBL] [Abstract][Full Text] [Related]
54. Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials.
Panettieri RA; Sjöbring U; Péterffy A; Wessman P; Bowen K; Piper E; Colice G; Brightling CE
Lancet Respir Med; 2018 Jul; 6(7):511-525. PubMed ID: 29792288
[TBL] [Abstract][Full Text] [Related]
55. SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma.
Wechsler ME; Colice G; Griffiths JM; Almqvist G; Skärby T; Piechowiak T; Kaur P; Bowen K; Hellqvist Å; Mo M; Garcia Gil E
Respir Res; 2020 Oct; 21(1):264. PubMed ID: 33050928
[TBL] [Abstract][Full Text] [Related]
56. Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility.
Humbert M; Albers FC; Bratton DJ; Yancey SW; Liu MC; Hozawa S; Llanos JP; Kwon N
Respir Med; 2019; 154():69-75. PubMed ID: 31220806
[TBL] [Abstract][Full Text] [Related]
57. Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma.
Bacharier LB; Maspero JF; Katelaris CH; Fiocchi AG; Gagnon R; de Mir I; Jain N; Sher LD; Mao X; Liu D; Zhang Y; Khan AH; Kapoor U; Khokhar FA; Rowe PJ; Deniz Y; Ruddy M; Laws E; Patel N; Weinreich DM; Yancopoulos GD; Amin N; Mannent LP; Lederer DJ; Hardin M;
N Engl J Med; 2021 Dec; 385(24):2230-2240. PubMed ID: 34879449
[TBL] [Abstract][Full Text] [Related]
58. Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis.
Casale TB; Pacou M; Mesana L; Farge G; Sun SX; Castro M
J Allergy Clin Immunol Pract; 2019 Jan; 7(1):122-130.e1. PubMed ID: 30217529
[TBL] [Abstract][Full Text] [Related]
59. The efficacy and safety of reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: A systematic review and meta-analysis.
Li J; Wang F; Lin C; Du J; Xiao B; Du C; Sun J
J Asthma; 2017 Apr; 54(3):300-307. PubMed ID: 27435534
[TBL] [Abstract][Full Text] [Related]
60. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Bachert C; Han JK; Desrosiers M; Hellings PW; Amin N; Lee SE; Mullol J; Greos LS; Bosso JV; Laidlaw TM; Cervin AU; Maspero JF; Hopkins C; Olze H; Canonica GW; Paggiaro P; Cho SH; Fokkens WJ; Fujieda S; Zhang M; Lu X; Fan C; Draikiwicz S; Kamat SA; Khan A; Pirozzi G; Patel N; Graham NMH; Ruddy M; Staudinger H; Weinreich D; Stahl N; Yancopoulos GD; Mannent LP
Lancet; 2019 Nov; 394(10209):1638-1650. PubMed ID: 31543428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
